FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population

Cancer Epidemiology

Volumn 34, Issue 6, 2010, Pages 724-732

  Bodoor, Khaldon ^a   Ghabkari, Abdulhameed ^a   Jaradat, Ziad ^a   AlKhateeb, Asem ^a   Jaradat, Saied ^a   Al Ghazo, Mohammed A ^a   Matalka, Ismail ^a   Musleh, Hisham ^a   Haddad, Yazan ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Bladder cancer; FGFR3; Prognosis

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MUTANT PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; JORDAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JORDAN; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 78650169276     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.05.003     Document Type: Article

References (60)

1. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.L., et al. Global cancer facts & figures. Atlanta 2007.
2. Tarawneh M., Nimri O. Cancer incidence in Jordan 2007, Jordan Cancer Registry, Amman.
3. Begum G., Dunn J.A., Bryan R.T., Bathers S., Wallace D.M. Socio-economic deprivation and survival in bladder cancer. BJU Int 2004, 94:539-543.
4. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
5. Al-Sukhun S., Hussain M. Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol 2003, 47:181-193.
6. Sobin L.H., Wittekind C. TNM classification of malignant tumors 1997, Wiley-Liss, New York.
7. Reuter V.E. The pathology of bladder cancer. Urology 2006, 67:11-17.
8. MacVicar A.D. Bladder cancer staging. BJU Int 2000, 86(Suppl. 1):111-122.
9. Sanchez-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem 2004, 37:562-571.
10. Simerville J.A., Maxted W.C., Pahira J.J. Urinalysis: a comprehensive review. Am Fam Phys 2005, 71:1153-1162.
11. Cote R.J., Datar R.H. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol 2003, 46(Suppl. 1):S67-S83.
12. Spiess P.E., Czerniak B. Dual-track pathway of bladder carcinogenesis: practical implications. Arch Pathol Lab Med 2006, 130:844-852.
13. van Rhijn B.W., van der Kwast T.H., Vis A.N., Kirkels W.J., Boeve E.R., Jobsis A.C., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004, 64:1911-1914.
14. van Tilborg A.A., de Vries A., de Bont M., Groenfeld L.E., Zwarthoff E.C. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 2002, 198:352-358.
15. Hirao S., Hirao T., Marsit C.J., Hirao Y., Schned A., Devi-Ashok T., et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer 2005, 104:1918-1923.
16. van Oers J.M., Adam C., Denzinger S., Stoehr R., Bertz S., Zaak D., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006, 119:1212-1215.
17. Johnson D.E., Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993, 60:1-41.
18. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
19. Wuchner C., Hilbert K., Zabel B., Winterpacht A. Human fibroblast growth factor receptor 3 gene (FGFR3): genomic sequence and primer set information for gene analysis. Hum Genet 1997, 100:215-219.
20. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., Diez de Medina S.G., Cappellen D., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006, 27:740-747.
21. Hart K.C., Robertson S.C., Donoghue D.J. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 2001, 12:931-942.
22. L'Hote C.G., Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005, 304:417-431.
23. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000, 7:165-197.
24. Horton W.A., Garofalo S., Lunstrum G.P. FGFR3 signaling in achondroplasia: a review. Cells Mater 1998, 8:83-87.
25. d'Avis P.Y., Robertson S.C., Meyer A.N., Bardwell W.M., Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 1998, 9:71-78.
26. Vajo Z., Francomano C.A., Wilkin D.J. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000, 21:23-39.
27. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Amoros A., Tardon A., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
28. Tomlinson D.C., Baldo O., Harnden P., Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213:91-98.
29. van Oers J.M., Zwarthoff E.C., Rehman I., Azzouzi A.R., Cussenot O., Meuth M., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009, 55(3):650-658.
30. Zieger K., Dyrskjot L., Wiuf C., Jensen J.L., Andersen C.L., Jensen K.M., et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005, 11:7709-7719.
31. Ronchetti D., Greco A., Compasso S., Colombo G., Dell'Era P., Otsuki T., et al. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 2001, 20:3553-3562.
32. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
33. Lindgren D., Liedberg F., Andersson A., Chebil G., Gudjonsson S., Borg A., et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006, 25:2685-2696.
34. Bostwick D., Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002, 441:109-116.
35. Bakkar A.A., Wallerand H., Radvanyi F., Lahaye J.B., Pissard S., Lecerf L., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63:8108-8112.
36. Fox J., An R. S-PLUS companion to applied regression 2002, Sage, Thousand Oaks.
37. Landau S., Everitt B.S. A handbook of statistical analysis using SPSS 2004, Chapman & Hall/CRC, New York.
38. Matsumoto M., Ohtsuki Y., Ochii K., Seike Y., Iseda N., Sasaki T., et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 2004, 12:967-971.
39. Gomez-Roman J.J., Saenz P., Molina M., Cuevas Gonzalez J., Escuredo K., Santa Cruz S., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005, 11:459-465.
40. Mhawech-Fauceglia P., Cheney R.T., Fischer G., Beck A., Herrmann F.R. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006, 32:231-237.
41. van Rhijn B.W., Vis A.N., van der Kwast T.H., Kirkels W.J., Radvanyi F., Ooms E.C., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
42. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de Medina S., Van Rhijn B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001, 158:1955-1959.
43. van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002, 10:819-824.
44. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001, 61:1265-1268.
45. Tomlinson D.C., Hurst C.D., Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26:5889-5899.
46. Sternberg M.J., Gullick W.J. A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Eng 1990, 3:245-248.
47. You M., Li E., Hristova K. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. Biochemistry 2006, 45:5551-5556.
48. Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996, 15:520-527.
49. Sternberg M.J., Gullick W.J. Neu receptor dimerization. Nature 1989, 339:587.
50. Li E., Hristova K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006, 45:6241-6251.
51. Smith S.O., Smith C.S., Bormann B.J. Strong hydrogen bonding interactions involving a buried glutamic acid in the transmembrane sequence of the neu/erbB-2 receptor. Nat Struct Biol 1996, 3:252-258.
52. Smith S.O., Smith C., Shekar S., Peersen O., Ziliox M., Aimoto S. Transmembrane interactions in the activation of the neu receptor tyrosine kinase. Biochemistry 2002, 41:9321-9332.
53. He L., Hristova K. Pathogenic activation of receptor tyrosine kinases in mammalian membranes. J Mol Biol 2008, 384:1130-1142.
54. Bargmann C.I., Weinberg R.A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988, 7:2043-2052.
55. Gibbs L., Legeai-Mallet L. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. Biochim Biophys Acta 2007, 1773:502-512.
56. Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000, 20:516-522.
57. Zieger K., Wolf H., Olsen P.R., Hojgaard K. Long-term survival of patients with bladder tumours: the significance of risk factors. Br J Urol 1998, 82:667-672.
58. Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M., Pavone-Macaluso M., et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995, 31A:1840-1846.
59. Eltze E., Wild P.J., Wulfing C., Zwarthoff E.C., Burger M., Stoehr R., et al. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol 2009, 56(5):837-847.
60. Lamy A., Gobet F., Laurent M., Blanchard F., Varin C., Moulin C., et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006, 176:2686-2689.